Trevi hits 4-year high as chronic cough therapy succeeds in study

Trevi Therapeutics

10/03/2025 14:23

Updates

** Shares of therapy developer Trevi Therapeutics TRVI.O rise 40.5% to touch a four-year high of $6.04

** Co says its therapy, Haduvio, met the main goal in a mid-stage trial testing in patients with a type of chronic cough

** Currently, there are no approved treatments in the U.S. for coughing bouts that don't have an identifiable cause or those that persist despite treating underlying conditions

** GSK GSK.L is developing a chronic cough treatment, and Merck has an experimental drug for the disease that faced two FDA rejections in the past

** Brokerage Raymond James upgrades its rating to "strong buy" from "outperform"

** Up to last close, TRVI up 45.8% in the last 12 months

 (Reporting by Christy Santhosh and Siddhi Mahatole)

 ((Christy.Santhosh@thomsonreuters.com))